What is the 13F Pro Quality Score for SHC?

13F Pro ranks Sotera Health Co (SHC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View SHC's current score at https://13fpro.ai/company/SHC (free sign-up required for the full ranking).

Which hedge funds own the most SHC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of SHC include Sessa Capital IM, L.P., Darsana Capital Partners, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/SHC as soon as new 13F filings post.

Where does 13F Pro source SHC data?

All Sotera Health Co fundamentals and ownership data come directly from SEC EDGAR. Sotera Health Co files with the SEC under CIK 1822479. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is SHC in?

Sotera Health Co (SHC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives SHC's revenue?

Per Sotera Health Co's latest 10-Q filed with the SEC on 2026-08-06, the biggest revenue drivers are: Sterigenics ($211.6M, +8.6% YoY); Nelson Labs ($60.7M, +6.3% YoY); Nordion ($49.1M, +15.8% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/SHC.

What are SHC's largest expenses?

Sotera Health Co's latest 10-Q reports these as the largest expense items: Cost of revenues ($143.4M, +12.3% YoY); Interest expense, net ($34.4M, -15.4% YoY); SG&A expenses ($68.2M, -1.1% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is SHC research updated on 13F Pro?

SHC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Sotera Health Co(SHC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqmid

Institutional-grade research for retail investors

SEC EDGAR: CIK 1822479 SHC stock profile & AI dashboard →

13F Pro Quality Score

64.4/100

Rank #548 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

53.4/100

Profitability

77.3/100

Balance Sheet

70.1/100

Earnings Quality

80.7/100

Free Cash Flow

54.0/100

Institutional Flow

84.8/100

Revenue Scale

53.6/100

Dilution Risk

35.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why SHC Scores 64/100

exact factor attribution · 2026-09-11

SHC's composite is driven by profitability and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+4.1 pts

77th pct

Earnings quality

+3.1 pts

81th pct

Earnings growth

+2.4 pts

98th pct

Capital efficiency

+2.0 pts

70th pct

Institutional flow

+1.7 pts

85th pct

Revenue growth

+0.7 pts

53th pct

Free cash flow

+0.6 pts

54th pct

Scale

+0.5 pts

54th pct

Shareholder dilution

-0.8 pts

35th pct

Latest change (2026-08-07): 60 → 51 · ↓ Profit margin 68→51; ↓ Revenue growth 58→41

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in SHC

Events flagged as statistical outliers against SHC's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-07
SHC quality score dropped 8 points (60→51) on a new filing
View source filing →

SHC Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Sotera Health Co (SHC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SHC at 64.4/100 on a 32-signal composite quality model, placing it at rank #548 of 2,961 stocks — the top 25% of the AI-ranked universe. SHC scores in the top quartile across institutional flow (84.8), earnings quality (80.7), profitability (77.3). Shareholder dilution risk is elevated at 35.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Sotera Health Co reports quarterly revenue of $321.4M, net income of $53.6M, an operating margin of 24.3%. Top institutional holders of SHC by reported 13-F value include Sessa Capital IM, L.P., Darsana Capital Partners, BlackRock, based on the most recent SEC filings. SHC trades on the Nasdaq exchange and files with the SEC under CIK 1822479. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SHC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Sotera Health Co directly from SEC EDGAR. Sotera Health Co's 13F Pro composite quality score has ranged between 31 and 67 since 2022, currently 64.4 — an improving long-term trajectory across 64 quarterly and live scoring snapshots.

What's Driving SHC's Business? Latest 10-Q Breakdown

✓ 31/31 datapoints verified

AI-extracted from Sotera Health Co's 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Sotera Health posted Q2 revenue of $321.4M (+9.2% YoY) driven by pricing gains and volume growth across sterilization and lab services, with net income of $53.6M vs. $8.0M prior year.

Biggest Revenue Drivers

Sterigenics$211.6M+8.6% YoY

Favorable pricing of 4.3% and volume/mix of 2.7%, plus 1.6% from foreign currency.

Nelson Labs$60.7M+6.3% YoY

Pricing of 2.8% and volume/mix of 2.6%, with foreign currency contribution.

Biggest Revenue Drivers

Total revenue: $321.4M+9.2% YoY

Sterigenics$211.6M+8.6% YoY

Favorable pricing of 4.3% and volume/mix of 2.7%, plus 1.6% from foreign currency.

Nelson Labs$60.7M+6.3% YoY

Pricing of 2.8% and volume/mix of 2.6%, with foreign currency contribution.

Nordion$49.1M+15.8% YoY

Volume/mix of 13.6% from favorable Co-60 harvest schedule timing and pricing of 3.1%.

Largest Expense Items

Cost of revenues$143.4M+12.3% YoY

Higher employee compensation, depreciation from recently placed assets, and unfavorable foreign exchange impact.

Interest expense, net$34.4M-15.4% YoY

Lower interest rate on Term Loan after Amendment No. 7 repricing and $75M principal paydown.

SG&A expenses$68.2M-1.1% YoY

Decrease driven mainly by lower litigation and professional services expenses.

Amortization of intangible assets$3.0M-67.6% YoY

Decline due to certain intangible assets fully amortized in May 2025.

Margins: Gross margin improved to 55.4% in Q2 2026 from 56.7% in Q2 2025, primarily due to higher cost inflation and unfavorable foreign exchange, partially offset by pricing benefits. Operating margins benefited from lower amortization of intangible assets.

Watch Items from the Filing

Ethylene oxide tort litigation in California (Vernon): ~150 personal injury/wrongful death claims with First Plaintiff Group of 8 cases prioritized for trials scheduled January-April 2027; Georgia: ~500 claims pending with ongoing appeals on general causation; Illinois: ~15 cases at various stages; company states losses 'not probable' but future settlements are 'reasonably possible.'
Capital expenditures increased significantly to $92.6M for H1 2026 vs. $51.1M in H1 2025, driven by facility expansion and Co-60 projects; company expects continued elevated capex for growth initiatives.
Nordion segment exhibited strong growth (+15.8% Q2 YoY, +21.6% H1 YoY) but results are subject to timing volatility from Co-60 harvest schedules and infrequent large gamma system sales, which can vary significantly quarter-to-quarter.
Nelson Labs segment income margin declined to 32.4% in Q2 2026 from 34.2% in Q2 2025, and H1 margin fell to 30.4% from 32.9%, driven by lower volume/mix and higher direct costs despite pricing gains.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$321.4M

Net Income

Q2 2026

$53.6M

Free Cash Flow

Q2 2026

$42.0M

Operating Margin

Q2 2026

24.3%

ROIC

Q2 2026

11.1%

D/E Ratio

Q2 2026

3.24

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+5.7% YoY

$1.16BFY 2025

FY22 $1.00BFY23 $1.05BFY24 $1.10BFY25 $1.16B

Net Income

+75.6% YoY

$77.9MFY 2025

FY22 $-233.6MFY23 $51.4MFY24 $44.4MFY25 $77.9M

Operating Income

—FY 2025

FY22 $248.3MFY23 $276.7MFY24 $297.6MFY25 —

EPS (Diluted)

+68.8% YoY

$0.27FY 2025

FY22 $-0.83FY23 $0.18FY24 $0.16FY25 $0.27

Total Assets

+6.2% YoY

$3.26BFY 2025

FY22 $3.12BFY23 $3.13BFY24 $3.07BFY25 $3.26B

Total Debt

-3.7% YoY

$2.15BFY 2025

FY22 $2.14BFY23 $2.23BFY24 $2.24BFY25 $2.15B

Op. Cash Flow

+28.1% YoY

$287.2MFY 2025

FY22 $278.0MFY23 $-147.7MFY24 $224.2MFY25 $287.2M

Free Cash Flow

+230.8% YoY

$149.2MFY 2025

FY22 $95.6MFY23 $-362.7MFY24 $45.1MFY25 $149.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.16B +5.7%	$1.10B +4.9%	$1.05B +4.5%	$1.00B +7.8%	$931.5M +13.9%	$818.2M
Net Income	$77.9M +75.6%	$44.4M -13.6%	$51.4M +122.0%	$-233.6M -299.8%	$116.9M +402.7%	$-38.6M
Operating Income	—	$297.6M +7.6%	$276.7M +11.4%	$248.3M -3.3%	$256.7M +24.6%	$206.0M
EPS (Diluted)	$0.27 +68.8%	$0.16 -11.1%	$0.18 +121.7%	$-0.83 -302.4%	$0.41 +356.2%	$-0.16
Total Assets	$3.26B +6.2%	$3.07B -1.9%	$3.13B +0.4%	$3.12B +11.8%	$2.79B +1.0%	$2.76B
Total Debt	$2.15B -3.7%	$2.24B +0.2%	$2.23B +4.3%	$2.14B +22.8%	$1.74B -4.5%	$1.82B
Operating Cash Flow	$287.2M +28.1%	$224.2M +251.7%	$-147.7M -153.1%	$278.0M -1.3%	$281.5M +133.5%	$120.6M
Free Cash Flow	$149.2M +230.8%	$45.1M +112.4%	$-362.7M -479.5%	$95.6M -46.7%	$179.4M +167.4%	$67.1M

Get alerted when SHC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Sotera Health Co including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of SHC

Sessa Capital IM, L.P.
$480.1M27,050,000 sh
Darsana Capital Partners LP
$479.3M27,000,000 sh
BlackRock, Inc.
$428.6M24,148,424 sh
Sculptor Capital LP
$426.0M24,000,000 sh
Sachem Head Capital Management LP
$276.2M15,560,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$216.0M12,170,699 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$212.0M11,946,341 sh
T. Rowe Price Investment Management, Inc.
$186.7M10,518,373 sh
AQR CAPITAL MANAGEMENT LLC
$186.4M10,734,313 sh
Jupiter Topco LLC
$149.1M8,402,106 sh

Fund	Value	Shares
Sessa Capital IM, L.P.	$480.1M	27,050,000
Darsana Capital Partners LP	$479.3M	27,000,000
BlackRock, Inc.	$428.6M	24,148,424
Sculptor Capital LP	$426.0M	24,000,000
Sachem Head Capital Management LP	$276.2M	15,560,000
VANGUARD CAPITAL MANAGEMENT LLC	$216.0M	12,170,699
VANGUARD PORTFOLIO MANAGEMENT LLC	$212.0M	11,946,341
T. Rowe Price Investment Management, Inc.	$186.7M	10,518,373
AQR CAPITAL MANAGEMENT LLC	$186.4M	10,734,313
Jupiter Topco LLC	$149.1M	8,402,106

Companies Similar to SHC

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

STE

STERIS plc

AI score

Similar quality profile · 5 shared holders

T. Rowe Price Investment Management, Inc.Retirement Systems of Alabama NORDEA INVESTMENT MANAGEMENT AB

INDV

Indivior Pharmaceuticals, Inc.

AI score

Similar quality profile · 8 shared holders

Two Seas Capital LP OP Asset Management Ltd Elo Mutual Pension Insurance Co

GMED

GLOBUS MEDICAL INC

AI score

Similar quality profile · 6 shared holders

Sculptor Capital LP Retirement Systems of Alabama STATE TREASURER STATE OF MICHIGAN

JAZZ

Jazz Pharmaceuticals plc

AI score

Similar quality profile · 5 shared holders

Retirement Systems of Alabama Weiss Asset Management LP CenterBook Partners LP

EHC

Encompass Health Corp

AI score

Similar quality profile · 15 shared holders

JENNISON ASSOCIATES LLC VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.T. Rowe Price Investment Management, Inc.

LIVN

LivaNova PLC

AI score

Similar quality profile · 10 shared holders

Retirement Systems of Alabama NORDEA INVESTMENT MANAGEMENT AB STATE TREASURER STATE OF MICHIGAN

PEN

Penumbra Inc

AI score

Similar quality profile · 9 shared holders

Sculptor Capital LP Retirement Systems of Alabama Weiss Asset Management LP

PGNY

Progyny, Inc.

AI score

Similar quality profile · 8 shared holders

Militia Capital Management LLC NORDEA INVESTMENT MANAGEMENT AB CenterBook Partners LP

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put SHC on your watchlist

Track score changes the day Sotera Health Co files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is SHC a good stock to buy?

13F Pro's AI-powered analysis of Sotera Health Co (SHC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SHC are available on the SHC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SHC is classified as a mid company.

Which hedge funds own SHC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SHC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Sotera Health Co's investment landscape.